Effectiveness and Safety of Perampanel as Early Add-On Treatment in Patients with Epilepsy and Partial Seizures in the Routine Clinical Practice: Spain Prospective Study (PERADON)
Abstract number :
1.317
Submission category :
7. Antiepileptic Drugs / 7C. Cohort Studies
Year :
2019
Submission ID :
2421312
Source :
www.aesnet.org
Presentation date :
12/7/2019 6:00:00 PM
Published date :
Nov 25, 2019, 12:14 PM
Authors :
Javier F. Abril, Centro de Neurologia Avanzada; Javier F. Abril, Centro de Neurologia Avanzada; Juan C. Estevez, H. Reina Sofia de Cordoba; Juan Giron, Hospital de Valme; Oscar Vega, H de la Cruz Roja; Elena Calzado, Clinica Beiman Jerez; Hernando Perez,
Rationale: Objective. Perampanel (PER) has been shown to be effective as adjunctive therapy for controlling refractory partial-onset seizures. However, the information as early add-on for the treatment of partial-onset seizures in the clinical practice is still scarce and must be further assessed. Methods: Methods. An observational prospective study was conducted to evaluate the effectiveness of early add-on PER, assessed as responders (seizures frequency reduced by at least 50%) rate at 6 and 12 months, in patients with epilepsy and partial seizures in the routine clinical practice of Spain. Safety was also assessed. Results: Results. 113 patients (mean age 40.3 years, 51.3% male) with epilepsy and partial seizures received PER as early add-on (1st add-on 37.2% and 2nd 62.8%) for a mean of 11 months. At 12 months, 68.1% of the patients were responders and 26.5% were seizure free. The retention rate at 6 and 12 months was 83.2% and 80.5%, respectively. The percentage of seizure-free patients at 12 months was significantly higher (p=0.033) when PER was added as first than as second add-on. The number of concomitant AEDs was significantly reduced from baseline to 6 and 12 months (p=0.001). Treatment was simplified in 23.9% of patients at the end of the observation period and 4.4% were converted to PER monotherapy. Drug-related AEs were present in 30.1% of patients, with irritability (8%), dizziness (7.1%), and behavior disorders (4.4%) being the most frequent ones. Conclusions: Conclusions. PER as early add-on for treatment of partial seizures showed high efficacy rates (>=50%-response rate 68.1% and 26.5% seizure free at 12 months) in the routine clinical practice, also treatment was simplified in 23.9% of patients, while keeping a safe profile. Funding: WE HAVE RECEIVED RESOURCES TO GENERATE RESEARCH WITHIN THE RESEARCH GROUP
Antiepileptic Drugs